Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

NCT03515798 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Breast Cancer

Interventions

DRUG: Pembrolizumab Injection
DRUG: neoadjuvant EC-paclitaxel chemotherapy

Sponsor

Institut Paoli-Calmettes

Collaborators

[object Object]
[object Object]